Author:
Kaira Kyoichi,Naito Tateaki,Takahashi Toshiaki,Ayabe Eriko,Shimoyama Rai,Kaira Rieko,Ono Akira,Igawa Satoshi,Shukuya Takehito,Murakami Haruyasu,Tsuya Asuka,Nakamura Yukiko,Endo Masahiro,Yamamoto Nobuyuki
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference34 articles.
1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005
2. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine inhibitor, in patients with five selected solid tumor types;Baselga;J Clin Oncol,2002
3. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies;Hidalgo;J Clin Oncol,2001
4. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib;Cho;J Clin Oncol,2007
5. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献